Developing microbiome-directed therapeutics for treating childhood undernutrition
Developing microbiome-directed therapeutics for treating childhood undernutrition
Abstract
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
Learning objectives
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
- Understand evidence that impaired postnatal development of the gut microbiota is causally related to childhood undernutrition
- Understand how preclinical gnotobiotic animal models can be used to develop new microbiota-directed therapeutics
- Understand how multiomic methods, including SomaScan® Assay proteomics, can be used to judge the efficacy and mechanism of action of these therapeutics in clinical studies
Jeffrey Gordon, MD
Director, Edison Family Center for Genome Sciences and Systems Biology, Washington University
Michael J. Barratt, PhD
Executive Director, Center for Gut Microbiome and Nutrition Research, Washington University
Developing microbiome-directed therapeutics for treating childhood undernutrition
A webinar presented by Jeffrey Gordon, MD, and Michael J. Barratt, PhD
Request more information
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.